# Administration of Rifaximin to Improve Liver Regeneration and Outcome Following Major Liver Resection

> **NCT02555293** · PHASE2 · TERMINATED · sponsor: **RWTH Aachen University** · enrollment: 96 (estimated)

## Conditions studied

- Malignant Liver Disease
- Major Liver Resection

## Interventions

- **DRUG:** XIFAXAN® (Rifaximin)

## Key facts

- **NCT ID:** NCT02555293
- **Lead sponsor:** RWTH Aachen University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-02
- **Primary completion:** 2020-11-20
- **Final completion:** 2020-11-20
- **Target enrollment:** 96 (ESTIMATED)
- **Why stopped:** Prematurely terminated due to organisational reasons
- **Last updated:** 2021-11-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02555293

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02555293, "Administration of Rifaximin to Improve Liver Regeneration and Outcome Following Major Liver Resection". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02555293. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*